MARYLAND / RankWire.AI / – U.S. Food and Drug Administration has authorized Rasonque, also known as daraxonrasib, for specific adult patients suffering from metastatic pancreatic adenocarcinoma. This decision was announced on August 26, 2026. The approval applies to individuals who have undergone at least one prior systemic treatment and also extends to those unable to tolerate multiagent systemic therapy. Developed by Revolution Medicines, this oral medication targets the RAS GTPase family, with a recommended dose of 300 milligrams once every day.
Researchers based their approval on the Phase 3 RASolute 302 trial, which involved 500 adults with metastatic pancreatic adenocarcinoma whose disease had progressed following one systemic therapy line. Participants were randomly assigned to either daraxonrasib (248 patients) or physician-chosen chemotherapy (252 patients). The median overall survival for those on daraxonrasib was 13.2 months, whereas patients receiving chemotherapy had a median survival of 6.7 months. The hazard ratio for death was 0.40, indicating a significant benefit from the targeted therapy.
Additional key efficacy measures also favored daraxonrasib. The median progression-free survival was 7.2 months for the treatment group, compared to 3.6 months in the chemotherapy arm. The objective response rate was notably higher at 30% with daraxonrasib versus 11% with chemotherapy. Statistically significant differences were observed across overall survival, progression-free survival, and response rate, supporting the clinical basis for FDA approval in previously treated metastatic pancreatic cancer cases.
Clinical trial results endorse the approval of targeted therapy
Daraxonrasib functions by blocking active RAS proteins, which are often implicated in cancer progression. RAS mutations are present in more than 90% of pancreatic ductal adenocarcinomas. The prescribing details do not specify that patients must have a particular RAS mutation to receive this treatment. Patients continue therapy until disease progression or intolerable side effects occur. Revolution Medicines designed Rasonque as an oral drug to serve this specific patient group, offering a targeted option following initial systemic treatments.
Safety data from the Phase 3 trial also played a role in the regulatory decision. Grade 3 or more severe adverse events were observed in 61.8% of daraxonrasib-treated patients, compared to 69.6% among those on chemotherapy. Treatment discontinuation due to adverse events was lower with daraxonrasib, at 1.2%, versus 11.2% in the chemotherapy group. Common side effects reported included rash, diarrhea, nausea, fatigue, vomiting, abdominal pain, decreased appetite, edema, mouth inflammation, and bleeding.
International collaboration influenced the FDA’s review process
The prescribing information for Rasonque includes warnings for serious adverse risks such as skin and soft tissue toxicity, oral disorders, severe diarrhea, and gastrointestinal perforation. Additional concerns involve interstitial lung disease or pneumonitis and embryo-fetal toxicity. The FDA utilized expedited oncology review pathways, including the Real-Time Oncology Review and the Commissioner’s National Priority Voucher pilot, completing the approval approximately 6.5 months ahead of its regulatory target date.
The FDA also examined the application through Project Orbis, which promotes coordinated review among international cancer regulatory agencies. Health Canada participated in the review process, with European and Japanese regulators serving as official observers. In addition, daraxonrasib received Breakthrough Therapy and Orphan Drug designations in the United States. This approval provides eligible U.S. patients with access to Rasonque after prior systemic therapy or when multiagent therapy is unsuitable. The Phase 3 trial demonstrated a median overall survival of 13.2 months, compared to 6.7 months with chemotherapy.